Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer
Anahtar kelimeler
Öz
Açıklama
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that does not express estrogen, progesterone, or the human epidermal growth factor (HER2/neu) receptors, and has a low overall survival rate compared to other types of breast cancer.
Unlike hormone and HER2/neu positive breast cancers, targeted therapies are not available for TNBC. Thus, the systemic chemotherapeutic agent doxorubicin is widely used for the treatment of TNBC. However, doxorubicin resistance is common, and leads to poorer treatment outcomes.
Understanding factors that contribute to doxorubicin resistance is critical to improving cancer treatment outcomes among women with TNBC. Pre-clinical in vitro studies indicate that exposure to endocrine disrupting chemicals, such as bisphenols and phthalates, contribute to doxorubicin resistance, but these findings have not been evaluated in humans.
Tarih
| Son Doğrulandı: | 06/30/2020 |
| İlk Gönderilen: | 02/10/2020 |
| Tahmini Kayıt Gönderildi: | 02/11/2020 |
| İlk Gönderilen: | 02/12/2020 |
| Son Güncelleme Gönderildi: | 07/20/2020 |
| Son Güncelleme Gönderildi: | 07/22/2020 |
| Fiili Çalışma Başlangıç Tarihi: | 08/31/2020 |
| Tahmini Birincil Tamamlanma Tarihi: | 07/31/2021 |
| Tahmini Çalışma Tamamlanma Tarihi: | 07/31/2021 |
Durum veya hastalık
Müdahale / tedavi
Other: Study cohort
Evre
Kol Grupları
| Kol | Müdahale / tedavi |
|---|---|
| Study cohort urinary bisphenol and phthalate levels | Other: Study cohort Collect three urine samples either in the clinic or at home. This will occur prior to starting neoadjuvant chemotherapy, and again at the end of the scheduled course of neoadjuvant chemotherapy. |
Uygunluk kriterleri
| Çalışmaya Uygun Yaşlar | 21 Years İçin 21 Years |
| Çalışmaya Uygun Cinsiyetler | Female |
| Örnekleme yöntemi | Non-Probability Sample |
| Sağlıklı Gönüllüleri Kabul Ediyor | Evet |
| Kriterler | Inclusion Criteria: - diagnosis of stage I - III triple negative breast cancer - scheduled to receive a neoadjuvant chemotherapy regimen including doxorubicin - receiving treatment at the George Washington University Cancer Center Exclusion Criteria: - diagnosis of other types of breast cancer - not scheduled to receive doxorubicin as part of the neoadjuvant chemotherapy regimen - not planning to receive neoadjuvant chemotherapy at the George Washington University Cancer Center |
Sonuç
Birincil Sonuç Ölçütleri
1. urinary bisphenol and phthalate metabolite levels [baseline]
2. urinary bisphenol and phthalate metabolite levels [post-neoadjuvant chemotherapy (either 16 or 20 weeks)]
3. change from baseline urinary bisphenol and phthalate levels at end of neoadjuvant chemotherapy [baseline and post-neoadjuvant chemotherapy (16 or 20 weeks)]
